{"id":14120,"date":"2011-09-18T10:30:00","date_gmt":"2011-09-18T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/francia-ristrutturazione-in-pfizer-a-rischio-1-500-isf\/"},"modified":"2011-09-18T10:30:00","modified_gmt":"2011-09-18T08:30:00","slug":"francia-ristrutturazione-in-pfizer-a-rischio-1-500-isf","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/francia-ristrutturazione-in-pfizer-a-rischio-1-500-isf\/","title":{"rendered":"France: restructuring in Pfizer, 1,500 Isf at risk"},"content":{"rendered":"<p><font size=\"4\">Pfizer&#039;s French subsidiary expects further job cuts due to the expiration, in May 2012, of the anti-cholesterol patent Tahor (atorvastatin \u2013 <em>Torvast, Lipitor, Totalip, Xarator<\/em>). According to the Ministry of Health, this measure would affect around 1,500 hospital ISFs, out of a total of 4,000 people. In 2009, Pfizer fired around 700 people in France, 600 of whom were ISF. Tahor&#039;s sales in 2010 reached \u20ac423 million, an increase of 3.2% compared to 2009.<\/font><\/p>\n<p>(Les Echos Pag.21 \u2013 14\/09\/2011, Les Echos online \u2013 14\/09\/2011)<\/p>","protected":false},"excerpt":{"rendered":"<p>La filiale francese di Pfizer prevede il taglio di ulteriori posti di lavoro a causa della scadenza, a maggio 2012, del brevetto dell&#8217;anticolesterolo Tahor (atorvastatina &#8211; Torvast, Lipitor, Totalip, Xarator). Secondo il Ministero della Salute questa misura riguarderebbe circa 1.500 Isf ospedalieri, su un totale di 4.000 persone. Nel 2009 Pfizer ha licenziato circa 700 &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14120","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14120"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14120\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}